Integra Lifesciences receives consensus rating of “buy”: 4 things to know

Analyst Ratings.Net shows that Integra Lifesciences has been given a consensus rating of “buy” by the seven ratings firms that are currently covering the company, according to a report by The Legacy.

Advertisement

Here are four things to know about the company’s stock:

 

•    The average one-year price target is $64.57, among brokers who have revised their coverage on the stock in the last year.
•    The company has a one-year low of $43.55 and a one-year high of $63.
•    The stock’s 50-day moving average is $60 and its 200-day moving average is $54.
•    The company has a market cap of $2.03 billion.

 

More articles on devices:
Bacterin’s Q1 total net revenue up again — 5 key takeaways
NuVasive shares’ mean target price set at $54
Bacterin, Zimmer, SpineGuard & more — 19 key notes

 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.